Novo Nordisk | NVO - Trade Debtors


Novo Nordisk reported DKK17.56B in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
ANI Pharmaceuticals USD 274.47M 19.04M Jun/2026
Aurora Cannabis CAD 44.58M 3.68M Mar/2026
Bausch Health Companies USD 2.26B 72M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Canopy Growth CAD 36.29M 104.13M Mar/2026
Corcept Therapeutics USD 76.92M 37.85M Jun/2026
Drreddys Laboratories INR 123.17B 121.76B Mar/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
GlaxoSmithKline GBP 8.07B 137M Jun/2026
Merck USD 12.21B 435M Mar/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Novartis USD 9.85B 252M Jun/2026
Novo Nordisk DKK 114.94B 8.68B Jun/2026
Novo Nordisk DKK 17.56B 82.7B Jun/2026
Pacira USD 132.42M 6.78M Jun/2026
Perrigo USD 697.1M 84.3M Mar/2026
Phibro Animal Health USD 215.87M 2.02M Dec/2025
Prestige Brands USD 187.36M 4.56M Jun/2026
Sanofi EUR 492M 10M Jun/2026
Supernus Pharmaceuticals USD 211.66M 29.47M Jun/2026
Zoetis USD 1.57B 65M Jun/2026